ETV Bharat / state

Followed all procedures to manufacture medicine, didn't advertise it: Acharya Balkrishna

By

Published : Jun 26, 2020, 6:58 AM IST

|

Updated : Jun 26, 2020, 9:50 AM IST

Defending the benefits of Coronil, Acharya Balkrishna, Chief Executive Officer of Patanjali, stated that all procedures laid down by the government were followed to manufacture the medicine and the products were not advertised.

Acharya Balkrishna

Acharya Balkrishna

Haridwar (Uttarakhand): Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, said that all procedures were followed to manufacture the medicine, Coronil, and they have not done anything wrong while obtaining the licence.

"We have followed all procedures to manufacture the medicine (Coronil). We applied for the licence based on classical evidence of the compounds used in the medicine. We worked on the compounds and put out the results of the clinical trial before people," Acharya Balkrishna said.

"We have not done anything wrong while obtaining the licence. We did not advertise the medicine (Coronil), we just tried to tell people about the effects of the medicine," he added.

Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali

This comes after MoS for the Union Ayush Minister Shripad Naik said that Patanjali Ayurved should not have advertised its newly-launched ayurvedic drugs for COVID-19 before getting final approvals.

Also read: Amid 'Coronil' row, Patanjali claims it broke no rules

"They (Patanjali Ayurved) should not have advertised it (Coronil) before getting final approvals. We have asked them to complete the requisite procedures. They have sent it to us and we will make a decision soon," Naik said.

Coronil

Coronil

The AYUSH Ministry had said on Tuesday that it has taken cognizance of news in the media about Ayurvedic medicines developed for the treatment of COVID-19 by Patanjali Ayurved Ltd, Haridwar and said the company has been asked to "stop advertising/publicising such claims till the issue is duly examined".

Patanjali Ayurved on Tuesday launched 'Coronil and Swasari' claiming it to be Ayurvedic cure for treating COVID-19 and said clinical trials have shown favourable results.

ANI report

Haridwar (Uttarakhand): Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, said that all procedures were followed to manufacture the medicine, Coronil, and they have not done anything wrong while obtaining the licence.

"We have followed all procedures to manufacture the medicine (Coronil). We applied for the licence based on classical evidence of the compounds used in the medicine. We worked on the compounds and put out the results of the clinical trial before people," Acharya Balkrishna said.

"We have not done anything wrong while obtaining the licence. We did not advertise the medicine (Coronil), we just tried to tell people about the effects of the medicine," he added.

Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali

This comes after MoS for the Union Ayush Minister Shripad Naik said that Patanjali Ayurved should not have advertised its newly-launched ayurvedic drugs for COVID-19 before getting final approvals.

Also read: Amid 'Coronil' row, Patanjali claims it broke no rules

"They (Patanjali Ayurved) should not have advertised it (Coronil) before getting final approvals. We have asked them to complete the requisite procedures. They have sent it to us and we will make a decision soon," Naik said.

Coronil

Coronil

The AYUSH Ministry had said on Tuesday that it has taken cognizance of news in the media about Ayurvedic medicines developed for the treatment of COVID-19 by Patanjali Ayurved Ltd, Haridwar and said the company has been asked to "stop advertising/publicising such claims till the issue is duly examined".

Patanjali Ayurved on Tuesday launched 'Coronil and Swasari' claiming it to be Ayurvedic cure for treating COVID-19 and said clinical trials have shown favourable results.

ANI report

Last Updated : Jun 26, 2020, 9:50 AM IST

TAGGED:

Acharya Balkrishna

Acharya Balkrishna

Copyright © 2024 Ushodaya Enterprises Pvt. Ltd., All Rights Reserved.